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INTRODUCTION 
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INTRODUCTION 
 
Obstetrics is a fine art built on the facts gathered by scientific 
research. In the era of modern Obstetrics where there has been a rapid 
advancement in all specialities, preterm labour remains an enigma for the 
obstetricians of today. 
The social and emotional cost of perinatal mortality and morbidity 
associated with preterm birth is immeasurable.  Ideally preterm labour 
should be prevented. However pharmacological inhibition of preterm 
labor remains an effective method to delay preterm delivery and improve 
neonatal outcome until a most effective means of prevention is identified. 
Since the Tocolysis has both potential benefits and side effects to neonate 
and mother, their use should be based on well designed controlled clinical 
studies. 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
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AIM OF THE STUDY 
 
Aim of care around preterm birth does not always involve 
prevention of preterm labour and birth. In situation where clinical 
condition makes it desirable to prolong pregnancy, primary out come 
considered is time saved to  
v Seek advice from a perinatal care unit  
v Institute therapy to improve fetal lung maturity  
v If necessary move mother to centre with neonatal intensive care 
unit 
Preterm fetus need glucocorticoids to enhance lung maturity .This 
can be achieved if delivery is postponed by 24 - 48 hours. Inhibition of 
uterine contraction at least for 2 days may therefore be regarded as 
optimal acute tocolysis.  A great number of drugs are used to inhibit 
preterm labour.  Aim of our study is to  
v Evaluate the effect and safety of transdermal nitroglycerine in 
acute tocolysis  
v Effect of transdermal nitroglycerine on maternal and neonatal 
outcome  
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
DRUG PHARMACOKINETICS 
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REVIEW OF LITERATURE 
DEFINITION  
Preterm labour is defined as the onset of regular, painful, frequent, 
uterine contractions causing progressive effacement and dilatation  of 
cervix occurring before 37 completed weeks of gestation from the first 
day of last menstrual period.1  Any infant born before 37 completed 
weeks should be called as preterm (WHO 1969). 
The lower limit which correlates with the fetal viability is less 
clearly defined. In United States it is 20 weeks. Royal College of 
Obstetricians and Gynecologist (RCOG) working party considered it as   
24 week. In India for legal purposes of viability it is defined as any 
gestation beyond 28 weeks (196 days). 
 
INCIDENCE    
The incidence of pre term labour in developed countries is between 
5% to 10%.  The incidence in India being 10-14% (FOGSI). In Annal 
Gandhi Memorial Hospital, Trichy, Incidence of Preterm Labour is 12%. 
IMPACT OF PRETERM BIRTH 
The most common maternal effects are feeling of inadequacy at 
fulfilling a reproductive role, more so in women who suffered recurrent 
pregnancy loss and development of postpartum endometritis.2 
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RISK TO PRETERM INFANT3 
§ Birth Asphyxia 
§ RDS 
§ Apnea of prematurity 
§ Jaundice  
§ Hemorrhage 
§ Metabolic problem 
§ Intraventricular/ Intracerebral 
hemorrhage 
§ PDA  
§ Necrotizing enterocolitis 
§ Retrolental fibroplasia 
§ Sensorineural deafness 
§ Developmental Delay 
§ Reduced growth potential 
§ Recurrent respiratory infections 
§ Learning difficulties 
§ Sudden infant death syndrome 
§ Cerebral Palsy 
§ Enforced separation of mother 
and baby 
 
It is not uncommon for the smallest surviving infant to incur 
nursery bills needing several hundred thousand dollars.4 
 
ETIOLOGY 
Only when the factors causing prematurity are clearly understood, 
any intelligent attempt at prevention can be made. 
Nearly 50-60% preterm births occur following spontaneous labour.  
30% is due to preterm rupture of membranes and the rest are iatrogenic. 
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One of the major reasons for increase in incidence of preterm birth 
is increase in multiple pregnancies (fertility drugs and artificial 
reproductive technology) and increased surveillance and intervention in 
high risk pregnancies  
 
1. Infections 5 
Chorioamnionitis6 20-30% 
Bobitt and ledger first suggested that unrecognized 
chorioamnionitis may be casually related to preterm labour.  They 
documented positive cultures during amniotomy via transcervical needle 
aspiration or intra uterine catheter.  The common pathway of intrauterine 
infection is the ascending route. 
Asymptomatic bacterial vaginosis and Trichomonas vaginalis 
confers a modest risk of spontaneous preterm labour (CDC). Bacterial 
vaginosis has association with low birth weight.  
High prematurity rate is associated with Asymptomatic bacteriuria.   
Colonisation of genital tract with group B streptococcus7 infection 
is associated with preterm labor. 
Colonisation with Chlamydia trachomatis (Martin et al.,8 Harrison        
et al., 14) Mycoplasma hominis (Klein et al.,9 Harrison et al.,) and 
Ureaplasma Urealyticum10 are associated with preterm labour.  
 6 
Edward et al.,11 reported higher incidence of positive gonorrhoea 
culture in preterm labour. 
 
Extrauterine 
Systemic illness like pneumonia, pyelonephritis. Periodontal 
disease is associated with preterm labour. 
 
2. Placental 
· Anatomical abnormalities  
· Placenta praevia 
· Abruptio placenta 
                                                                                                                                                         
3. Uterine 
· Congenital abnormalities 1-3% 
· Incompetent Cervix 
· Over distention 
 4. Genetic (Genes for Decidual Relaxin /Fetal mitochondrial 
Trifuntional protein defect, IL-1, β2 adrenergic receptor gene, tumor 
necrosis factor –α are implicated).  
 5. Vaginal bleeding in early pregnancy is associated with preterm 
labour. 
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6. Fetal 
Congenital Anomalies 
 
7. Preterm Labour of unknown origin 20-30% 
 
PATHOPHYSIOLOGY  
  The control of parturition is achieved by complex integration of 
endocrine, paracrine and autocrine mechanism. 
1. The fetal pituitary adrenal axis needs to be intact. 
2. The role of oxytocin and oxytocin – prostaglandin interaction is 
still unclear (Fuch’s et al., 1984).12 
 Cox and colleagues13 (1993) found that cytokines (1LI, 1L6, 
TNFα, IL8) are released when there is inflammatory response to infection 
and intrauterine bleeding. These inturn stimulate arachidonic acid and 
prostaglandin production. 
 Differential production of PGE2 and PGF2 by the three enzymes – 
phospholipases, PGH2 synthase, 15 hydroxy prostaglandin dehydrogenase 
may be a key in the balance between uterine quiescence and activity.  
This decidual activation and production of uterotropins is the penultimate 
event in initiation of labour.14 
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EPIDEMIOLOGY 
1. Race15 
The incidence is greater among black women. 
 
2. Age  
It is more common in extremes of age.  Lumley et al., 1993 
reported high incidence of preterm delivery in women under 20 years and 
over 35 years. 
 
3. Weight 
Poor nutrition, prepregnancy weight and weight gain during 
pregnancy play an important role in causing preterm birth.  Hickey and 
colleagues 1995, have shown low maternal prenatal weight gain is 
specifically associated with preterm birth. 
 
4. Stature 
Short statured mothers have more tendency to produce smaller 
babies. 
 
5. Socio-Economic Status 
Women from lower socio economic status tends to be less educated 
and would not have satisfactory general or antenatal care and hence more 
incidence of preterm labour. 
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6. Addictions 
Women who smoke cigarettes or who abuse cocaine are at 
increased risk of preterm labour (Bakketing and Hoffman, 1981).16 
7. Occupational Factors 
Those involved in manual work are more prone for preterm labour.  
PREDISPOSING FACTORS 
1. Stress 
Careers which involve physical fatigue and high psychological 
stress are associated with increased incidence of preterm labour.17  
Prolonged standing decreases uteroplacental blood flow and increases the 
frequency of uteroplacental insufficiency causing growth retardation. 
Preterm birth is increased in women living alone, and in those who are 
subjected to physical abuse. 
2. Coitus18 
Coitus was not found to be associated but increasing numbers of 
sexual partners increased the risk of recurrent preterm delivery. 
3. Reproductive History 
a. Previous preterm Birth 
The history of one previous preterm birth is associated with 
recurrent risk of 16-41% and the risk increases with the number of 
preterm birth and decreases with the number of term deliveries.19 
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b. Previous abortion 
There is an increase in the incidence of preterm deliveries in 
women who experience one or more second trimester abortions. 
c. Cervical incompetence  
d. Uterine anomalies 
 
4. Pregnancy complications 
· Multiple pregnancies  
· Hydramnios  
· Preclampsia 
· Antepartum hemorrhage 
· Second trimester bleeding  not due to placental causes  
 
5. Interpregnancy interval20 
A significant increase in preterm birth was observed when the 
interval between previous child birth and LMP of next pregnancy was 
less than 3 months. 
 
6.  Fetal Gender 
The main fetal factor influencing the rate of preterm delivery is 
fetal sex in the preponderance of males delivering preterm.  
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RISK SCORING SYSTEM  
A risk scoring system devised by Papiernik and modified by 
Creasy and Govik21 (1986) has been tested in several regions. Women 
with scores of 10 or more are considered to be at high risk for preterm 
labour.  
Scoring systems is based on the factors which increase the risk of 
preterm delivery, the risk is highest with a previous preterm delivery. 
Bleeding in pregnancy, Urinary tract infections, higher order pregnancies, 
body mass index < 20kg /m2, previous low birth weight babies and stress 
(family illness, mortality, violence, financial) are associated with preterm 
delivery.  Unfortunately risk scores don’t identify the majority of women 
who deliver preterm.  They are of limited clinical use. 
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PAPIERNIK RISK SCORING SYSTEM 
Points Socio-economic factors 
Previous 
Medical History Daily Habits 
Aspects of Current 
Pregnancy 
1 
Two children at 
home, Low socio-
economic status 
Abortion × 1, 
less than 1 yr 
since last birth  
Works outside  Unusual Fatigue 
2 
Maternal age < 20 
yrs or > 40yr, Single 
parent 
Abortion × 2 
Smokes more 
than10cigarettes 
per day, more 
than 3 flights of 
stairs without 
elevator  
Gain of <5Kg by 32 
weeks  
3 
Very low socio-
economic status  
Height <150cm 
Weight<45 kg 
Abortion ×  3 
Heavy or 
stressful work 
that is long and 
tiring, Extensive 
traveling, long 
daily 
commuting 
Breech at 32 wks 
Weight loss, Head 
engaged at 32 wks, 
Febrile illness. 
 
4 Maternal age               < 18 yrs  Pyelonephritis  
Bleeding after 12 
weeks, Short 
Cervix, Opened 
internal OS, Uterine 
irritability. 
5  
Uterine anomaly, 
Second trimester 
abortion, DES 
exposure, cone 
biopsy 
 Placenta previa, Hydramnios  
10  
Preterm delivery, 
Repeated second 
trimester abortion 
 Twins, Abdominal surgical procedure 
 
 13 
PREDICTION OF PRETERM LABOUR 
1. CERVICAL ASSESSMENT 
Asymptomatic cervical dilatation after mid pregnancy has gained 
attention as a risk factor for preterm delivery.  Leveno22 and associates 
found that one fourth of the women whose cervices were dilated 2 to             
3 cm between 26 and 30 weeks delivered before 34 weeks.  By routine 
cervical examination the sensitivity of predicting preterm labour is 63% 
in nullipara and 53% in multipara. 
 
2. UTERINE ACTIVITY MONITORING 
Katz23 and associates found that women who had subsequent 
preterm delivery had increased uterine contraction at 30 weeks. 
Home uterine contraction monitoring was investigated by many 
and found to be successful.  Currently ACOG (1995) has not clearly 
demonstrated the usefulness of this expensive and burdensome system in 
preventing preterm labour. 
 
3. FIBRONECTIN 
The presence of fetal fibronectin in cervicovaginal secretions has to 
be proposed as a specific predictor of preterm labour.  (Lockwood and 
Coworkers, 1991).24  It can be measured using ELISA and values 
exceeding 50mg/ml are considered positive result.  However of most 
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concern is the high false positive rate with microscopic contamination 
with amniotic fluid or semen, maternal blood and in patients with 
cerclage. The test is more accurate in predicting spontaneous preterm 
birth within 7-10 days in women with symptoms of threatened preterm 
labour before advanced cervical dilatation.  
           The high negative predictive value of fetal fibronectin can be used 
to influence management. 
 
4. USG 
Honest et al.,25 found that in asymptomatic women 
ultrasonography measurement of cervical length using cut off of 25 mm 
or less between 20-24 weeks gestation is likely to be accurate in 
predicting spontaneous preterm birth.  
 
BIOCHEMICAL MARKERS 
 
1. Salivary oestriol : Progesterone ratio 
2. Serum Collagenase 
3. Tissue inhibitor of metalloproteinase (TIMP)  
4. Relaxin 
5. Corticotrophin releasing hormone (CRH) 
6. Mediators of inflammation and infection.  
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a. CRP26 
b. Leucocyte esterase 
c. Cytokines27 
d. Amniotic fluid glucose concentration 
e. Zinc 
f. Lipocortin – 1 
g. Positive cultures 
These are not practically helpful in prediction of preterm labour. 
 
DIAGNOSIS OF PRETERM LABOUR 
1. Symptoms of preterm labour28 
· Menstrual like cramps 
· Low, dull back ache 
· Abdominal cramping 
· Change in vaginal discharge 
· Uterine contractions that are 10 minutes apart or closer 
Cunningham GH and coworkers (2001) found that preterm labour 
is considered to be established if regular uterine contractions can be 
documented at least 4 in 20 minutes or 8 in 60 minutes with progressive 
change in cervical score with effacement 80% or more and dilatation 
more than 1 cm. 
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If there is absence of cervical change in the presence of 
contractions the condition is Threatened Preterm Labour. 
 
2. Pelvic examinations 
3. Ultrasonogram 
Ultrasonogram assessment in preterm labour. 
· Fetal viability  
· Gestational age 
· Estimated fetal weight 
· Indicators of preterm labor – Cervical Length and width of           
internal os 
· Amniotic fluid volume 
· Number of fetus  
· Fetal presentation and lie 
· Fetal movement and tone 
· Fetal gender 
· Fetal anomaly 
· Placental localisation and morphology 
· Uterine fibroid  
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4. Toco Cardiography 
The amplitude, duration, frequency of contraction, and basal tone 
are monitored.  The uterine activity is expressed in Montevideo units.  
 
PREVENTION OF PRETERM LABOUR 
1. Basic Care 
· Support system of family and friends should be developed 
· Numerous suggestions on coping with physical and mental stresses 
of maintaining a  pregnancy should be described 
· Education, supportive services from health care providers and 
financial issues are also of common concern.  
· Behavioural and lifestyle modification  
a. Smoking cessation  
b. Avoidance of illicit drugs  
c. Adequate nutrition 
 
2. Bed rest and Hydration  
Although bed rest and hydration are widely used as the first step of 
prevention and treatment, there is no evidence that this practice is 
beneficial. 
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Bed rest should be advised with caution after evaluating its benefits 
and risks in an individual, and not routinely keeping in mind its adverse 
effects like venous thrombosis and pulmonary edema. 
 
3. Aggressive treatment of cervicovaginal infection  
Bacterial vaginosis has been consistently associated with a 1.5 to 3 
times increased risk of spontaneous preterm birth.  But the efficacy of 
treatment in reduction of preterm birth is conflicting.  But recent 
systematic review showed that screening and treatment of asymptomatic 
bacteruria and bacterial Vaginosis in low risk population may reduce the 
rate of preterm deliveries. 
 
4. Cervical Encerclage 
A short cervix diagnosed by ultrasound in asymptomatic women 
may be an indication for cerclage. The role of cervical cerclage for the 
prevention of preterm delivery is now disputed as cerclage has a inherent 
risk which actually increase preterm labour by increasing the pericervical 
inflammation or infection. 
 
5. Progesterone  
Weekly intramuscular administration to women at high risk for 
preterm labour resulted in lower rates of preterm birth and perinatal   
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mortality when compared to placebo.  The dose used was 250 mg of             
17-hydroxy progesterone caproate intramuscularly every week from 20 to 
36 weeks. 
 
MANAGEMENT OF PRETERM LABOUR29 
a. Bed rest and hydration 
b. Steroids 
In 1994, a National Institute of Health Consensus Development 
Panel recommended corticosteroids for fetal lung maturation in preterm 
labour.30  Since then, there has been nearly universal acceptance and 
implementation of these recommendations. 
All pregnant women between 24 and 34 weeks of gestation who 
are at risk of preterm delivery within 7 days should be considered 
candidates for antenatal corticosteroids. 
Recommended regimens includes a single course of two doses of 
12 mg of betamethasone given intramuscularly 24 hours apart, or four 
doses of 6mg of dexamethasone given intramuscularly 12 hours apart. 
A Cochrane Systematic Review found that antenatal corticosteroids 
reduce neonatal death, respiratory distress syndrome, intraventricular 
hemorrhage. Also antenatal corticosteroid is not associated with changes 
in the rates of maternal death, maternal infection, fetal death, neonatal 
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chronic lung disease or birth weight. It is also associated with a reduction 
in incidence of neonatal enterocolitis and systemic infections in the first 
48 hours of life as well as reduction in the need for respiratory support or 
neonatal intensive care unit admission. 
Although benefit on neonatal outcome is maximum between              
24 hours and 7 days after initiation of therapy, steroids confer significant 
survival advantages even when delivery occurs within 24 hours. 
Therefore treatment should not be withheld when delivery is probable 
within 24 hours. 
c. Tocolysis - In early preterm labour to provide time for steroids to 
act 
 
Tocolysis is pharmacological suppression of unwanted uterine 
activity.  
 
Criteria for tocolytic therapy 
· Gestational age between 20 and 34 weeks from LMP 
· Expected fetal weight less than 2kg by ultrasonography 
· Membranes intact 
· Cervical dilatation less than 3 cm. 
· Alive uncompromised fetus  
· Regular uterine contraction with progressive cervical changes. 
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TOCOLYTICS IN PRETERM LABOUR31 
1. PROGESTOGENS 
Fuch and Stakeman (1960), Brenner and Hendricks (1962), 
Olivesen and Hell et al. (1975) have investigated the use of progestogens 
and were unable to show any inhibitory effect on uterine contraction.  
Johnson et al.32 (1975) found that 17 αOH progesterone caproate was able 
to prevent preterm labour.  Two recent metaanalysis indicate that 
progestogenic agents reduce the occurrence of preterm birth.   
 
2. ETHANOL33 
Fuch et al. (1967) the principal advocate of this mode of therapy 
gave a loading dose of ethanol followed by maintenance dose for further 
10 hours.  The over all success rate was 65%.  Complications include 
nausea, vomiting, headache and restlessness. They act centrally by 
decreasing the amount of oxytocin. 
 
3. BETA SYMPATHOMIMETICS 
Rucker in 1925 noted that small doses of epinephrine inhibited 
uterine hyperactivity.  Efforts to produce an epinephrine like compound 
which lacked the cardiovascular stimulant effect culminated in the 
synthesis of β agonists. 
I generation : Isoxsuprine, orciprenaline, Isoprenaline 
 22 
II generation: Ritodrine,34 Terbutaline,35 Fenoterol. 
 Unfortunately in terms of clinical effectiveness the inhibition of 
contractions by β adrenergic agonists is often short lived. 
 
Maternal side effects 
· Tachycardia 
· Hypotension 
· Cardiac arrhythmias 
· Myocardial ischaemia 
· Pulmonary edema 
 
Contraindications 
· Symptomatic cardiac disease especially ventricular outflow 
obstruction 
· Conduction disturbance 
· Hyperthyroidism 
· Sickle cell disease 
· Uncontrolled IDDM 
· Chorioamnionitis 
· Eclampsia or severe preeclampsia 
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· Multifetal gestation 
· Severe obstetrical bleeding 
· Severe Anaemia 
· Patients on MAO inhibitors 
· Asthmatic patients already on β adrenergic agents. 
 
MAGNESIUM SULPHATE 
MgSO4 uncouples the depolarization contraction coupling (Elliott, 
1983).36  Most commonly used for the prevention and treatment of 
seizure in preeclampsia but its tocolytic effect recognized since 1959. 
Therapeutic level for both indications is 4-8 m mol per litre.  Increased 
concentration than this leads to neuromuscular blockade, respiratory 
depression, cardiac arrest. It crosses placenta and new born baby may be 
drowsy. 
 
PROSTAGLANDIN SYNTHETASE INHIBITORS 
Drugs like aspirin, indomethacin37 are used as an alternative to β 
agonist to prevent preterm labour in patients with cardiac disease and 
hyperthyroidism.  Not routinely used because of fear of PDA closure and 
pulmonary hypertension in fetus.  
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CALCIUM CHANNEL BLOCKERS38 
They are heterogenous group of organic compounds that inhibit the 
influx of extracellular calcium across the cell membrane during inward 
calcium current of action potential.  They also inhibit the release of 
intracellular calcium from the sarcoplasmic reticulum.  Thus they reduce 
the tone of smooth muscles. 
 The commonly used drug Nifedipine is a potent inhibitor of 
myometrial contractions in non pregnant, pregnant and post partum 
uterus. 
 
Side effects 
· Dizziness 
· Flushing 
· Headache 
· Peripheral Edema 
· Fetal hypoxia  
 
OXYTOCIN ANTAGONIST (ATOSIBAN)39 
There will be increase in myometrial oxytocin receptors in labour.  
This analogue competitively blocks the oxytocin receptors and inhibits 
preterm labour. RCOG guidelines suggest that if tocolytics are 
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administered, the first choice should be oxytocin antagonists or 
Nifedipine.  But compared with other tocolytics atosiban therapy is 
costly. 
 
NITRIC OXIDE DONORS (GLYCERYL TRINITRATE)40 
The Nitric Oxide donors inhibit corticotrophin releasing hormone 
secretion which acts as a promoter of parturition.  This was listed at 
Kings College Hospital (Lees et al., 1994).41 
 Nitric Oxide is an endogenously occurring biatomic molecule and 
can be given in the form of nitric oxide donor.  First recorded use of nitric 
oxide donor in pregnancy was reported in British journal 1882 when amyl 
nitrite was used to deliver morbidly adherent placenta. Nitroglycerine 
used intravenously as uterine relaxant to aid breech extraction. Breech 
extraction was facilitated by Nitroglycerine spray (Lancet 1991). 
Nitroglycerine spray was also used to assist in replacing an inverted 
uterus in case of retained placenta. 
 Nitric Oxide donors causes smooth muscle relaxation and effect on 
uterine muscle is more pronounced during pregnancy than delivery.  
 
POTASSIUM CHANNEL OPENERS 
These newer group of drugs which hyperpolarize excitable tissues 
and function as potent smooth muscle relaxant. Maximum inhibition is 
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achieved at micromolar concentration.  The outward current of potassium 
offsets depolarizing stimuli and so suppress the regenerative electrical 
activity thereby rendering the myometrial cell quiescent. Further 
evaluation is needed. 
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DRUG PHARMACOKINETICS 
NITROGLYCERINE PATCH 
Recent reports indicate that nitric oxide released from L-arginine is 
central to inhibit uterine activity during gestation. Taking this fact into 
consideration, it was thought that perinatal salvage can be dramatically 
improved by using transdermal nitroglycerine as a tocolytic agent. 
 
MECHANISM OF ACTION 
Organic nitrates are rapidly denitrated enzymatically in smooth 
muscle cell to release nitric oxide which activates Guanyl cyclase thereby 
increasing CGMP which causes dephosphorylation of myosin light chain 
kinase (MLCK). Reduced availability of phosphorylated MLCK interfere 
with activation of myosin. It fails to interact with actin to cause 
contraction.  Consequently relaxation occurs. Raised intracellular CGMP 
may also reduce calcium entry contributing to relaxation. 
 
ROLE OF NITRIC OXIDE IN PREGNANCY 
Nitric oxide is basically responsible for relaxation of smooth 
muscle in myometrium. The myometrial concentration of nitric oxide 
increases significantly in early pregnancy. But in late pregnancy, there is 
a decrease in nitric oxide level in myometrium and decidua. Therefore 
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contractile status increases towards term. Conrad et al localized nitric 
oxide in syncytio trophoblast of human placenta. 
Recently it has been established that Nitric oxide as EDRF plays a 
very important role in uteroplacental circulation. It decreases both 
resistance and pulsatility index in both umbilical and uterine arteries and 
thereby increases uteroplacental blood flow.  
 
COMPOSITION 
Transdermal (TTS) containing 25 mg (TTS-5), 50 mg (TTS-10) 
and 75 mg (TTS-15) are available for use. 
 
PROPERTIES 
TTS is a flat multi layered patch designed to deliver nitroglycerine 
continuously through a release membrane. TTS-10 denotes normal 
amount of Nitroglycerine in mg delivered by system / 24 hours. When 
Nitroglycerine content is 50 mg, rate of drug release / hour is 0.4 mg.  
 
ABSORPTION 
Following single application, placental concentration of 
Nitroglycerine reaches a plateau at 2 hours and is maintained for                  
24 hours. It has bioavailability of 70-90%.  
 
 29 
DISTRIBUTION 
Same plasma levels are obtained regardless of site of application of 
patch and distribution of drug is equal. 
 
METABOLISM 
Transdermal Nitroglycerine is rapidly metabolized by glutathione 
dependent organic nitrate reductase in liver and excreted in urine.  
 
ELIMINATION 
Plasma concentration drops below the level of detection within            
1 hour of removal.  
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
 It is a prospective randomized controlled trial.  The study was 
conducted in Annal Gandhi Memorial Hospital, Trichy from August 2008 
to July 2009.  100 patients with preterm labour randomly selected from 
patients attending antenatal OPD and from labour ward.  50 patients 
recruited for nitroglycerine patch and another 50 patients for bed rest 
alone.  Both the groups received intramuscular corticosteroids. In view of 
the ethical issue, written informed consent was obtained. 
 
INCLUSION CRITERIA 
1. Gestational age between 28 to 34 wks as determined by menstrual 
dates, clinical examination, USG. 
2. Uterine contractions: 2 contractions in 10 minute period, each 
contraction lasting for 40 sec. 
3. Progressive cervical effacement upto 75%. 
4. Cervical dilatation upto 3 cm. 
5. Intact membranes. 
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EXCLUSION CRITERIA 
Maternal Factors 
1. Rupture of Membrane  
2. Infection 
3. Cervical dilatation greater than 3 cm 
4. Antepartum hemorrhage 
5. Pregnancy induced hypertension 
6. Chronic hypertension 
7. Cardiac disease 
8. Previous caesarean section 
9. Renal disease 
10. Pulmonary disorder – Asthmatics, ARDS. 
 
Fetal Factors 
1. Multiple gestation 
2. Fetal death / distress 
3. IUGR 
4. Congenital anomalies 
5. Polyhydramnios / Oligohydramnios 
6. Erythroblastosis 
 32 
Investigations 
1. Urine analysis 
2. Complete Blood count 
3. Vaginal swab 
4. USG 
 
DRUG PROTOCOL  
On admission, patients were put in left lateral position.  BP, pulse 
rate recorded.  CVS, RS examined. 
 
GROUP A 
 5 mg of Nitroglycerine patch applied to the skin of the abdomen.  
Even after 1 hour, if there was no decrease in the frequency and strength 
of uterine contractions, an additional patches were applied.  Maximum 
dose is 20 mg in 24 hours.  Patches were removed after 24 hours and 
same number of fresh patches were applied for the next 24 hours. 
 
Treatment discontinued if 
· BP falls < 90 / 60 mm Hg 
· PR > 100 / min 
· Patient had PROM  
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· Uterine contractions persist for > 24 hours even after applying 20 
mg of Nitroglycerine patch. 
 
GROUP B 
Observed with bed rest. 
 
Common for Group A & B 
2 doses of Betamethasone42 12 mg IM 24 hours apart is given. 
 
Monitoring 
Maternal     Fetal 
Pulse Rate    Heart Rate 
Blood Pressure   Rhythm 
Uterine contractions  Tone 
All were monitored every 30 mins for 1st 2 hours.  Then every 2 
hours for 12 hours. Then 4 hourly for 48 hours. 
 
Side effects of Nitroglycerine Patch 
v Headache 
v Tachycardia 
v Hypotension 
v Dizziness 
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v Weakness 
v Skin irritation 
 
Definition of Success 
Treatment is considered successful if uterine contraction subsided 
and tocolysis achieved for > 48 hours.    
 
Definition of failure 
The therapy was said to have failed when the patient delivered 
within 48 hours of initiation of therapy.  Tocolytic was stopped when 
cervical dilation progressed to > 3 cms or when the membranes ruptured 
spontaneously. 
Hence this study confines itself to the study of idiopathic 
spontaneous preterm labour, comparing the efficacy of nitroglycerine 
patch with that of control group in prolonging pregnancy for atleast             
48 hours and studying the maternal and fetal effects. 
 
 
 
 
 
 
 
 
 
 
 
NITROGLYCERIN PATCH 
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ANALYSIS OF RESULTS 
Study was designed with total sample of randomly selected 100 
cases who were in Preterm labour, out of which 50 females were 
randomly allotted for Nitroglycerine patch in group A and another 50 
patients in group B observed with bed rest alone.  All patients on study 
were given corticosteroids.  Prophylactic antibiotics also were given to all 
patients.  After inspection of pooled outcome data, the following results 
were observed. 
AGE DISTRIBUTION 
Table - 1 
Group A Group Age in 
Years No. % No. % 
Total 
< 20 8 16 5 10 13 
20-24 26 52 24 48 50 
25-29 11 22 14 28 25 
30-34 2 4 4 8 6 
>35 3 6 3 6 6 
Total 50 100 50 100 100 
P value = 0.764 
Age distribution of 2 groups of patients had no much significant 
difference.  P value - 0.764 (> 0.05).  Majority of patients in both the 
groups fall in the age group 20-24 yrs.  The mean age group of study 
subjects was 23.9 years. 
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SOCIOECONOMIC STATUS 
Patients from SES V constituted 75%, SES IV 15%, SES III 10%. 
Preterm labour is common in low socio economic and nutritional status.  
 
SOCIO-ECONOMIC STATUS 
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ANTENATAL CARE 
 
Table - 2 
Group A Group B S. 
No. ANcare No. % No. % 
1. Unbooked 28 56 28 56 
2. Booked 22 44 22 44 
P value = 0.5 
 
Preterm labour was more common among unbooked patients while 
the booked patients who had atleast 3 visits were educated about preterm 
labour and complications.  Regular antenatal care was received by 44% of 
patients in both Group A & B. 
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PARITY 
Table - 3 
Group A Group B S. 
No. Gravida No. % No. % 
1 P 28 56 26 52 
2 G2 11 22 16 32 
3 G3 08 16 06 12 
4 G4 03 06 02 04 
 Total 50 100 50 100 
P value = 0.686 
 
Parity selection did not have much significant difference in both 
groups (P > 0.05) Primi 56% in Group A and 52% in Group B.  Multi-
44% in Group A and 48% in Group B. 
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PREVIOUS HISTORY OF PRETERM LABOUR 
Table - 4 
Group A Group B S. 
No. H/O PTL No. % No. % 
1. Yes 6 12% 7 14% 
2. No 44 88% 43 86% 
P value = 0.5 
 
There was no significant difference in history of Preterm labour 
between 2 groups of patients.  Majority of patients selected for this study 
experienced preterm labour for the first time. 
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PRESENTATION 
Table - 5 
Group A Group B S. 
No. Presentation No. % No. % 
1. Cephalic 46 92% 45 90% 
2. Breech 4 8% 5 10% 
P value = 0.5 
 
Maximum number of patients in both the groups had cephalic 
presentation. 
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GESTATIONAL AGE 
Table - 6 
Group A Group B S. 
No. 
Gestational 
Age No. % No. % 
1. 28-30 wks 10 20% 7 14% 
2. 31-32 wks 23 46% 18 36% 
3. 33-34 wks 17 34% 25 50% 
P value = 0.058 
 
Time of prolongation of pregnancy varied considerably with 
Gestational age at entry in both groups.  20% of patients in group A and 
14% in group B had gestational age of 28-30 weeks.  46% in group A and 
36% in group B belonged to gestational age 31-32weeks.  In 33-34 weeks 
there were 34% of patients in group A and 50% in group B. 
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DURATION OF PROLONGATION 
Table - 7 
Group A Group B S. 
No. Duration No. % No. % 
1. 48 - 72 hrs 16 32% 10 20% 
2. 72 hrs - 1 wk 15 30% 5 10% 
3. 1-2 wks 10 20% 4 8% 
4. 2-3 wks 3 6% 1 2% 
5. >3 wks 2 4% 0 0 
P value = 0.014 
 
Prolongation beyond 1 week was observed in 30% in group A and 
10% in group B.  Mean duration of prolongation of pregnancy in Group 
A was 6.6 days. 
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RESPONSE ACCORDING TO GESTATIONAL AGE 
Table – 8 
Group A Group B S. 
No. 
Gestational 
Age Success Failure Success Failure 
1. 28-30wks 7(70%) 3(30%) 2(28.5%) 5(71.5%) 
2. 30-34wks 39(97.5%) 1(2.5%) 18(41.8%) 25(58.1%) 
P value = 0.031 
 
In 30-34 wks of Gestation, pregnancy was prolonged in 97.5% and 
41.8% in case and control group respectively. In 28-30 wks of Gestation, 
pregnancy was prolonged in 70% in group A and 28.5% in group B.             
P value is 0.031 which is statistically significant. 
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PROLONGATION OF PREGNANCY 
Table - 9 
Group A Group B S. 
No. Gestational Age No. % No. % 
1. <36 wks 45 90 % 49 98% 
2. >36 wks 5 10 % 1 2% 
P value = 0.037 
 
Pregnancy was prolonged to > 36 wks in 10% and 2% in group A 
and group B respectively.  P value is less than 0.05. 
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SUCCESS OF ACUTE TOCOLYSIS 
Table - 10 
Group A Group B S. 
No. Duration No. % No. % 
1. < 48hrs 4 8% 30 60% 
2. > 48hrs 46 92% 20 40% 
P value = 0.014 
 
The success of tocolysis in group A and group B were 92% and 
40% respectively.  P value was found to be 0.01 which is statistically 
significant. 
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DOSAGE REQUIRED TO SUBSIDE CONTRACTIONS 
Table - 11 
Group A S. 
No. 
Drug Dosage to Subside 
Contractions No. % 
1. 5 mg patch 14 28% 
2. 10 mg patch 30 60% 
3. 15 mg patch 4 8% 
4. 20 mg patch 2 4% 
 
In our study 4% of patients needed 20 mg patch, 8% needed 15 mg 
patch, 60% needed 10 mg patch and 28% of patients needed 5 mg patch 
to subside uterine contractions and there by to prolong labour. 
 
 
 
 
 
 
 
 
  
 
DOSAGE REQUIRED TO SUBSIDE CONTRACTIONS 
 
28
60
8 4
5 mg patch 10 mg patch 15 mg patch 20 mg patch
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CERVICAL EFFACEMENT 
Table – 12 
Group A Group B S. 
No. Effacement Success Failure Success Failure 
1 25 15(93.75%) 1(6.25%) 12(60%) 08(40%) 
2 50 19(95%) 1(5%) 6(37.5%) 10(62.5%) 
3 75 12(85.7%) 2(14.2%) 2(14.2%) 12(85.7%) 
P value = 0.025 
 
In patients with 25% cervical Effacement, 93.75% in Group A and 
60% of patients in Group B showed prolongation of pregnancy. With 
50% Cervical Effacement, successful tocolysis was observed in 95% of 
patients in Group A and 37.5% of patients in Group B.  When the Cervix 
was 75% effaced, 85.7% in Group A and 14.2% in Group B had their 
pregnancy prolonged by more than 48 hours.  P value is 0.025 and it is 
statistically significant. 
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CERVICAL DILATATION 
Table - 13 
Group A Group B S. 
No. Dilatation Success Failure Success Failure 
1. < 2 cm 34(94.4%) 2(5.5%) 18(56.2%) 14(43.7%) 
2. 2 – 3 cm 12(85.7%) 2(14.2%) 2(11.1%) 16(88.8%) 
P value = 0.037 
 
When the cervix was < 2 cm dilated, 94.4% in Group A and 56.2% 
in Group B had their pregnancy prolonged by > 48 hours. With 2-3cm 
cervical dilatation, prolongation of pregnancy was observed in 85.7% in 
Group A and 11.1% in Group B.  P value is 0.037 (< 0.05) which is found 
to be statistically significant. 
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MATERNAL MORBIDITY AND MORTALITY 
Table – 14 
Group A S. 
No. Side Effects No. % 
1. Headache 20  40 
2. Dizziness 8  16 
3. Tachycardia 5  10 
4. Hypotension 1 02 
5. Skin Irritation 1  02 
 
There was no maternal mortality.  No case of postpartum 
hemorrhage was observed in those who delivered within 48 hours.  The 
most common side effect observed among patients in group A was 
headache (40%). 
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MODE OF DELIVERY 
Table - 15 
Group A Group B S. 
No. 
Mode of 
Delivery No. % No. % 
1. Vaginal 49 98% 50 100% 
2. Caesarean 1 2% - - 
 
98% and 100% of cases delivered vaginally in group A and group 
B respectively.  One case of group A underwent Caesarean section for 
PROM with no response to Oxytocin. 
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NEONATAL MORTALITY 
Table – 16 
Group A Group B S. 
No. 
Neonatal mortality 
among Babies born  No. % No. % 
1. < 48 Hrs 02 50% 10 33.3% 
2. > 48 Hrs 01 2.1% 03 15% 
P value = 0.04 
 
Neonatal mortality was 50% in group A and 33.3% in group B 
among babies born in failure group whereas it is 2.1% in group A and 
15% in group B among babies born in success group.  Neonatal morbidity 
and mortality are primarily influenced by gestational age and thus 
maturity and less so by birth weight.43  P value = 0.04 is statistically 
significant. 
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NEONATAL MORBIDITY 
Table – 17 
Group A Group B S. 
No. Complication No. % No. % 
1 Birth Asphyxia 3 06 5 10 
2 RDS 4 08 9 18 
3 Septicemia 2 04 5 10 
4 IVH - - 3 06 
P value = 0.014 
 
RDS as a complication of prematurity is observed in 8% of babies 
in group A and 18% of babies in group B.  The incidence of Birth 
Asphyxia is 6% in group A and 10% in group B.  4% of babes in group A 
and 10% in group B developed  Septicemia.  Intraventricular hemorrhage 
was observed in 6% of babies in group B. P value is 0.01 which is 
statistically significant. 
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APGAR SCORE 
Table – 18 
Group A 
Babies born in 
Group B 
Babies born in S. 
No. Apgar 
Success 
Group 
Failure 
Group 
Success 
Group 
Failure 
Group 
1 < 5 6 (13%) 2 (50%)  4 (20%) 18 (60%) 
2 5 – 6 10 (21.7%) 1 (25%) 10 (50%) 11 (36.6%) 
3 ³ 7 30 (65.2%) 1 (25%) 6 (30%) 1 (3.3%) 
P value = 0.027 
 
In group A 90.2% of babies had Apgar score of 7 and above where 
as only 33.3% of babies had Apgar score of 7 and above in group B.   
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WEIGHT OF BABY AT BIRTH 
Table – 19 
Group A Group B S. 
No. 
Weight of the baby 
in Kg. No. % No. % 
1. < 2  22 44 32 64 
2. 2 – 2.5  26 52 17 34 
3. > 2.5 02 04 01 02 
P value = 0.0173  
  
Most of the babies were born with a birth weight of 2 – 2.5 Kg. in 
group A (52%) where as in group B, most of the babies had birth weight 
of < 2 Kg. (64%).  P value is < 0.05 which is statistically significant. 
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DISCUSSION 
 
On analysis of data, tocolysis with transdermal nitroglycerine is 
considered safe with good therapeutic efficacy. 
When this data is compared to previous study, baseline 
characteristics did not differ significantly. In study by Lees et al., 
multiparous women were more than primi and in age distribution most 
were in 25-29 years. Gestational age at entry differed considerably in 
each study group. Study by Lees et al. (1994) it was 24-36 weeks.  In 
study by Krishna et al. (1996) Gestational age at entry varied from 18-34 
weeks. Rowlands44 (1996) in his study recruited patients with gestational 
age 16-32weeks.  In Campbell study (1994) duration of pregnancy varied 
from 23-33weeks.  In our study, patient recruited had Gestational age          
28-34 weeks.  Maximum no of patient were in 31-32 weeks of Gestation 
in Group A (46%) and in Group B (50%) were in 33-34 weeks of 
Gestation. 
Cervical dilatation in our study range from 0-3 cm where as in 
study by Rowlands (1996) Cervical dilatation ranged between                       
2-8 cm.  Campbell (1994) recruited patients in Cervical dilatation ranging 
from 0-4cm. Cervical dilatation influenced much on prolongation of 
pregnancy. When cervix is > 2 cm dilated tocolytic efficacy is minimal. 
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Lees (1994) Krishna et al. (1996) used10mg nitroglycerine patch 
where as Rowlands (1996) conducted study using 50 mg nitroglycerine 
patch.  In study conducted here 60% needed 10 mg patch and 4% needed           
20 mg patch.  In Lees et al. (1994) study main side effect of 
nitroglycerine was headache (30%) and in our study it was 40%. 
Success rate of acute tocolysis was 100% in study conducted by 
Krishna et al. (1996) for nitroglycerine.  Lees (1994) showed success 
95% for nitroglycerine as acute tocolysis.  In this study conducted here, 
success rate was 92% for nitroglycerine. 
Safety, efficacy, acceptability limits usage of drug.  Transdermal 
nitroglycerine is considered to be a safer drug for its ease of use, easy 
metabolism with no side effect besides headache. While efficacy was 
studied, Transdermal nitroglycerine act as a good acute tocolysis for 
effective action of corticosteroid and to provide time for the patient to get 
transferred to tertiary neonatal care unit. 
As a secondary analysis, an economic evaluation of trial was done. 
Both cost and consequence of treatment with nitroglycerine was 
evaluated.  Though nitroglycerine patch was little costlier, but compared 
to patient care in neonatal unit & hospital stay, it is cost effective.  
Nitroglycerine possible effect in delaying preterm delivery rate, 
good acute tocolytic efficacy, very minimal side effects, good neonatal 
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outcome makes the drug superior to other tocolytics. On complete 
analysis nitroglycerine is safe, easily applicable and acceptable by the 
patients. 
Rapid & effective action obtained with nitroglycerine patch, its 
simplicity, safety suggest that nitroglycerine has a major contribution in 
the management of preterm labor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 58 
SUMMARY 
 
In the randomized trial of Nitroglycerine patch in the prolongation 
of preterm labour, it was observed that. 
1. Preterm labour was common in primigravida in the age group            
20-24 years, belonging to lower socioeconomic status and who did 
not receive appropriate antenatal care.  
2. There were 80% of cases between 30-34 weeks in group A and 
86% in group B. 
3. Previous preterm delivery was found in 12% in group A and 14% 
in group B. 
4. 92% in group A and 90% in group B had cephalic presentation. 
5. The success of Nitroglycerine patch as indicated by prolongation of 
pregnancy beyond 48 hrs was observed in 92% of cases compared 
with 40% in controls. 
6. Nitroglycerine patch 10 mg was required in 60% of patients, 20 mg 
patch was required in 4% of patients to subside the uterine 
contractions.  
7. In 30-34 weeks of gestation, success was observed in 97.5% in 
group A and 41.8% in group B.  In 28-30 weeks, success rate was 
70% and 28.5% in group A & group B respectively. 
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8. When the cervix was 25% effaced, successful tocolysis was 
observed in 93.75% of cases in group A and 60% in group B. 
When cervix was 50% effaced, prolongation of pregnancy beyond 
48 hours was observed in 95% of patients in group A and 37.5% in 
group B. With 75% effacement, successful tocolytic effect seen in 
85.7% in group A and 14.2% in group B. 
9. When the cervix was < 2 cm dilated, prolongation of pregnancy 
beyond 48 hours was observed in 94.4% of cases in group A and 
56.2% in group B.  When the cervix was 2-3 cm dilated, successful 
tocolysis was observed in 85.7% and 11.1% of cases in group A 
and group B respectively.  Mean duration of prolongation of 
pregnancy in Group A was 6.6 days. 
10. Headache and dizziness were the commonest side effects observed 
in study group.  
11. There was no maternal mortality in both the groups.  
12. Neonatal mortality was due to complications of prematurity.  
Among success group, it was 2.1% in group A compared to 15% in 
group B. 
13. The percentage of cases delivered vaginally in group A and group 
B were 98% and 100% respectively. 
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14. Apgar of ³ 7% was observed in 90.2% of babies in group A and 
only 33.3% in group B. 
15. Babies with Birth weight > 2 kg were delivered in 56% and 36% in 
group A and group B respectively. 
16. The incidence of RDS in group A was 8% and in group B it was 
18%.  4% of babies in group A and 10% of babies in group B had 
septicemia. Birth asphyxia was observed in 6% and 10% of babies 
in group A and group B respectively. 
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CONCLUSION 
 
Labour inhibiting drugs may not treat the cause of preterm labour 
but they only treat the symptoms i.e. uterine contractions.  
As these agents make the uterus refractory to stimuli for a short 
time the perinatal outcome is improved. In this clinical trial, the 
idiopathic spontaneous preterm labour whose onset was at 30 to 34 weeks 
of gestation had responded well to tocolytic therapy and neonatal 
outcome improved and no maternal mortality was observed.  The 
maternal side effects were reversed on discontinuation of the drug.  The 
drug had provided the fetus a valuable opportunity of being inside the 
mother’s womb for a period enough to make the lungs mature by 
administration of exogenous steroids. 
However decrease in the incidence of preterm labour lies in the 
identification of high risk patients, improving the socio-economic 
standard, better antenatal care, education and early detection of the onset 
of preterm labour. 
On evaluation of transdermal nitroglycerine on acute tocolysis, it is 
found that nitroglycerine patch is absolutely safe and successful in 
achieving complete tocolysis. 
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Nitroglycerine is not only safe but also has a very minimal side 
effects like headache on mother.  It has no untoward side effect on 
neonate.  Neonatal outcome is good in all respects like apgar score, birth 
weight, less neonatal admission in nitroglycerine therapy. 
To conclude transdermal nitroglycerine has a very good role to 
play as an acute tocolytic in the treatment of preterm labour and should 
be considered as first line drug of choice. 
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PROFORMA 
 
NAME :      AGE : 
ADDRESS :      IP NO : 
 
DATE & TIME OF ADMISSION  : 
DATE & TIME OF DELIVERY  : 
DATE OF DISCHARGE   : 
OBSTETRIC CODE   : 
LMP      : 
EDD      : 
G.A      : 
BOOKED/UNBOOKED   : 
SOCIO ECONOMIC STATUS  : 
 
HISTORY OF PRESENT ILLNESS : 
1. Lower abdominal pain 
2. Vaginal discharge 
3. Fever 
4. Urinary tract infection 
5. Bleeding pv 
6. Draining pv 
7. Coitus 
 
MENSTRUAL H/O 
MARITAL H./O 
OBSTETRIC H/O: 
Previous obstetric outcome 
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PAST H/O: 
H/o preterm labour / Abortion – induced or spontaneous/ still birth 
DM/ heart disease/hypertension/TB/Epilepsy/renal disease  
PERSONAL H/O: 
 Smoker/Alcohol 
 
GENERAL EXAMINATION: 
Ø Pallor 
Ø Oedema 
Ø Febrile 
 
VITALS: 
Ø Temp  : 
Ø PR  : 
Ø BP  : 
Ø RR  : 
Ø Ht  : 
Ø Wt  : 
 
SYSTEMIC EXAMINATION 
CVS  : 
RS  : 
CNS  : 
ABDOMEN: 
P/A:  
Symphysio fundal ht 
Uterine size in wks 
Presenting part 
FHR 
EFW 
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P/V: 
Cervix :  
Effacement 
Dilatation 
Consistency 
Position 
Station 
Membrane 
Pelvis 
Draining pv/bleeding pv 
Bishop score 
 
INVESTIGATION: 
Urine – sugar/ albumin/microscopy/culture sensitivity 
Complete hemogram 
Blood sugar 
Blood urea 
Vaginal swab c/s: 
CTG: 
USG: 
Singleton/multiple 
Vertex/breech 
G.A 
AFI 
Placenta 
Congenital anomalies 
EFW 
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TOCOLYTIC      BED REST 
NTG PATCH 
APPLIED ON 
NO OF PATCHES 
GROUP A :  NITROGLYCERINE PATCH 
TIME DOSE CONTRACTION PR BP RR FHR 
       
       
       
       
       
 
 
COMPLICATIONS: 
Headache 
Tachycardia 
Hypotension 
Postural dizziness 
Weakness 
Skin rash 
 
FETAL OUTCOME 
Alive / Still Born  : 
Sex    : 
Mode of Delivery  : 
Birth Weight   : 
APGAR   : 
GROUP A GROUP B 
 73 
DELIVERED AT 
28-30 WKS 
30-32 WKS 
32-34 WKS 
34-36 WKS 
> 36 WKS 
 
TREATMENT DELIVERY INTERVAL 
 
NEONATAL MORBIDITY: Admitted / Not 
 
NEONATAL MORTALITY: Yes / No 
        : Cause 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
S. 
No. Name Age IPNo DOA Group 
Bo
ok
 st
at
us
 
Pa
rit
y 
H/
O 
PT
L 
GA
 at
 en
try
 (w
ks
) 
Pr
es
en
ta
tio
n 
Cx
 E
ff 
%
 
Cx
 D
il 
St
at
io
n 
Ma
t C
om
p 
B.
W
t i
n 
kg
 
GA
 at
 D
el 
(w
ks
) 
DO
P 
in
 d
ay
s 
Ap
ga
r 
Ne
o 
ou
tc
om
e 
1. Tamilselvi 26 32934 31.7.08 B UB G2 - 34 C 50 2F -3 - 2.1 34 1 6   
2. Nirosa 19 33166 2.8.08 A B P - 33 C 25 1F -3 H 2.4 36 21 8   
3. Vasanthi 27 33228 31.7.08 B UB G3 - 32 C 50 3Cm -1 - 1.8 32 18 hrs 4 III 
4. Kala 27 33996 7.8.08 A UB G3 - 34 C 25 1F -3 H 2.6 36 14 7   
5. Danalakshmi 26 34229 9.8.08 A UB G2 - 32 C 75 1Cm -1 H 1.5 32.2 2 6   
6. Anjalaiden 28 34167 9.8.08 B B G2 + 34 C 75 3Cm -1 - 2.2 34 5 hrs 8   
7. Radha 28 34960 13.8.08 A UB P - 34 C 50 2F -2 H 2.3 35.1 8 8   
8. Vijayalakshmi 22 35907 27.8.08 B UB G2 - 31 C 25 1F -3 - 1.5 31 3 5 I 
9. Deepa 36 36223 23.8.08 B UB G2 - 34 C 50 2Cm -1 - 2 34 12 hrs 6 II 
10. Tharamani 18 36346 25.8.08 A B P - 31 C 25 1F -3 - 2 33.6 20 8   
11. Sathyalatha 22 36343 25.8.08 A UB G2 - 33 C 50 2F 0 H 2.2 34.5 12 8   
12. Rani 36 36283 24.8.08 B UB G4 - 32 C 75 2Cm -3 - 1.5 32 8 hrs 4 III, V 
13. Latha 21 36686 27.8.08 A B P - 32 C 50 2F 0 BP¯ 2 33.6 13 8   
14. Umarani 26 36805 28.8.08 B UB G2 + 34 C 25 2F -2 - 2.1 34 1 6   
15. Tamilarasi 23 37208 30.8.08 A UB G2 - 34 C 50 2F -2 H 2.6 36 14 8   
16. Dilsath 28 37860 4.9.08 B B G3 - 31 C 50 2cm -2 - 1.4 31 18 hrs 4 II, V 
17. Saheethabanu 26 38191 6.9.08 B UB G2 + 29 C 25 2F -2 - 1.1 29 1 3 IV, V 
18. Pulalarasi 26 37886 5.9.08 A B G2 - 34 C 50 2F -2 D 2.2 34.6 6 8   
19. Dhanabakiyam 22 38759 10.9.08 A UB P - 31 C 25 1F -3 H 1.6 32 7 6   
20. Jothi 21 39986 18.9.08 A B P - 34 C 50 2F 0 H 2.5 36 14 8   
21. Manjula 23 40227 20.9.08 B B G2 - 31 C 75 3cm -1 - 1.4 31 5 hrs 4 III, V 
22. Rajeswari 22 40991 25.9.08 B UB P - 32 C 50 2F -1 - 1.5 32 1 4 II, V 
23. Sangeetha 27 40687 29.9.08 B B G2 - 29 C 25 1F -3 - 1.1 29.2 2 3 III, V 
24. Rani 19 41451 28.9.08 A B P - 32 C 25 1F -3 D 2 33.5 12 8   
25. Barakath 33 41523 29.9.08 B UB G3 + 34 C 75 3Cm -1 - 2.3 34 4 hrs 6   
26. Silambarasi 28 41680 29.9.08 A UB G3 - 34 C 25 1F -2 S.I 2.2 34.5 5 8   
27. Rajalakshmii 32 42283 3.1.08 B UB G3 - 32 C 75 3Cm -1 - 1.6 32 6 hrs 4 I 
28. Saratha 23 42713 6.1.08 A B P - 31 C 50 2F -2 - 1.5 31.2 2 5   
29. Kannammal 22 43122 9.1.08 A UB P - 32 C 50 2F -2 H 2 33.1 8 8   
30. Sahayamary 33 43680 13.1.08 B UB G4 - 31 C 25 1F -3 - 1.5 32 7 5 II 
31. Jayalakshmi 18 48323 14.1.08 A B P - 30 C 50 2F -2 - 1.4 31 7 5   
32. Shinnammal 19 44825 23.1.08 B UB P - 33 C 50 2F -2 - 1.8 33.2 2 6 II 
33. Chitra 21 44393 19.1.08 A UB P - 33 C 50 2F -1 D 2.2 34 7 8   
34. Ashrafnisha 18 45675 29.1.08 B B P - 32 C 25 1F -2 - 1.8 33.4 4 6   
35. Ranjiitha 23 46593 31.1.08 A B G2 - 34 C 50 2F -1 H 2.1 34.4 4 8   
36. Chitra 22 46557 3.11.08 B UB P - 29 Br 50 2Cm -1 - 1.1 29 1 3 IV, V 
37. Patchiammal 18 48029 12.11.08 B UB P - 32 C 25 2F -2 - 1.6 32.4 4 5 I 
38. Sankiliyammal 18 49622 19.11.08 A B P - 31 C 25 1F -3 - 2 33 14 8   
39. Rasia banu 21 47651 10.11.08 A UB P - 34 C 25 2F -1 - 2.5 36 14 9   
40. Sangeetha 19 47435 25.11.08 B UB P - 29 Br 50 2F -1 - 1.1 29 1 3 I, V 
41. Kanagasundari 18 50509 27.11.08 A B P - 30 C 50 2F -2 - 1.3 30.4 4 4   
42. Sudha 32 50518 27.11.08 B UB P - 31 C 25 1F -3 - 1.4 31.5 5 4 III 
43. Suganya 18 51506 5.12.08 B UB P - 32 C 25 1F -3 - 1.8 33.5 12 6   
44. Jothi 23 51883 8.12.08 A UB G2 - 33 C 25 2F -2 H 2.1 34 7 8   
45. Gnanarani 27 52832 12.12.08 B B G2 - 34 C 75 2Cm -1 - 2.2 34 5 hrs 6   
46. Vanitha 26 53340 16.12.08 A UB G2 - 30 C 75 2Cm -1 H 1.3 30.2 2 4 I 
47. Pitchiarani 28 104 1.1.08 B UB G2 - 34 C 25 1F -3 - 2.1 34.6 6 8   
48. Jeyabarathi 27 54686 26.12.08 A B G3 - 30 C 50 2F -1 - 1.3 30.4 4 5 II 
49. Barani 28 909 7.1.08 B B G2 + 29 Br 50 2F -1 - 1.2 29 1 3 II, V 
50. Valli 33 1038 8.1.08 A UB G4 - 32 C 25 2F -2 D 2 32.6 6 8   
51. Emalda 23 2259 19.1.08 A UB G2 - 34 C 75 2Cm -1 - 2.1 34.2 2 8   
52. Valliamal 26 3744 29.1.08 B UB G3 - 34 C 50 2Cm -1 - 2.1 34 1 6   
53. Benitharani 26 5265 9.2.08 A B G4 - 34 C 75 3Cm -1 D 2.1 34.1 1 6   
54. Thirumalai 28 5395 10.2.08 A UB G2 - 32 C 25 1F -3 H 2.4 36 28 8   
55. Rajakumari 28 680 18.2.08 B B G3 - 32 C 75 3Cm 0 - 1.6 32 6 hrs 4   
56. Deepa 27 6783 19.2.08 A UB G3 - 34 C 25 2F -2 D 2.1 34.3 3 8   
57. Shanthi 27 6411 19.2.08 B UB G2 - 32 C 50 2F -1 - 1.6 32.3 3 6   
58. Selvi 33 6805 17.2.08 A B G3 - 32 Br 50 2F -1 H 2 32.5 5 8   
59. Parameswari 22 8163 19.2.08 B B P - 34 C 75 2Cm -1 - 2.1 34 6 hrs 6   
60. Vijayalakshmi 264 10407 28.2.09 B UB G2 - 32 C 25 1F -3 - 1.7 32.4 4 5   
61. Kannaki 334 10965 13.3.09 A B G4 + 31 C 25 2F -2 H 1.5 31.2 2 5 II 
62. Banupriya 27 12079 17.3.09 B B G2 + 29 C 50 2F -1 - 1.2 29 1 3 I, V 
63. Nathiya 22 10708 24.3.09 A UB P - 30 Br 75 3Cm -1 - 1.3 30 12 hrs 4 I, V 
64. Dhowlath 22 12760 16.3.09 B B P - 31 C 50 2F -1 - 1.6 31.3 3 4 II, V 
65. Mariyammal 26 13306 28.3.09 A UB P - 32 C 50 2F -2 - 2 32.3 3 8   
66. Jubaidha 22 13393 1.4.09 B B P - 34 C 50 2F -2 - 1.9 34 1 4   
67. Dhanalaksmi 18 14122 1.4.09 A B P - 31 C 75 3Cm -1 - 1.5 31.2 2 7   
68. Sharmila begam 23 14355 6.4.09 B UB G2 + 30 C 25 2F -2 - 1.3 30 1 3 IV, V 
69. Basheera 36 14233 8.4.09 A UB G3 + 32 C 25 1F -2 H 1.7 32.4 4 7   
70. Vasantha 21 14726 7.4.09 B B P - 34 C 25 1F -3 - 2.6 36.2 16 9   
71. Lakshmi 22 14752 10.4.09 B UB P - 34 C 50 2F -1 - 1.9 34 2 2   
72. Malathi 23 15010 10.4.09 A B P - 33 C 50 2F -1 D 1.8 33.5 5 8   
73. Maheswari 22 15122 12.4.09 A UB P - 21 C 75 2Cm -1 T 1.7 32.2 2 7   
74. Aruna 23 15992 13.4.09 B B P - 34 C 50 2F -1 - 1.6 34 1 4   
75. Banumathi 36 16825 19.4.09 A B G3 + 31 C 25 1F -3 H 1.8 32.1 8 7   
76. Poongothai 21 17047 24.4.09 B B P - 31 C 25 2F -2 - 1.4 31.3 3 4 II, V 
77. Maria Anthoniyammal 23 16519 25.4.09 A UB G2 + 29 C 50 2F -2 - 1.1 29.2 2 3 II, V 
78. Alagu 21 17088 22.4.09 B UB P - 33 Br 75 3Cm 0 - 1.5 33 6 hrs 4 II, V 
79. Anandhi 18 17229 22.4.09 A B P - 32 C 75 3Cm -1 - 1.5 32 1 7   
80. Kokila 22 18102 27.4.09 B B P - 34 C 25 1F -2 - 2.2 35.3 10 8   
81. Banumathi 21 18052 2.5.09 A UB P - 34 C 75 2Cm -1 H 2.1 34.2 2 7   
82. Sornam 22 18163 2.5.09 A B P - 29 C 50 2F -1 D 1.3 29.6 6 3 III 
83. Kalaiselvi 23 19567 3.5.09 B UB P - 34 C 25 1F -3 - 2.3 35.1 8 8   
84. Nirmaladevi 22 20212 11.5.09 B B P - 34 C 75 3Cm -1 - 2.1 34 5 hrs 6   
85. Ariamala 23 20667 14.5.09 A UB P - 30 C 75 3Cm -1 T 1.3 30.2 2 4 II 
86. Nathiya 23 21314 18.509 B UB P - 33 Br 25 2F -2 - 1.9 33.3 3 6   
87. Saguntala 22 22963 22.5.09 A UB P - 22 Br 75 2Cm -1 H 2 32.2 2 5   
88. Kavitha 21 24967 1.2.09 B B P - 34 C 25 1F -3 - 1.5 34.3 3 7   
89. Rasathi 23 24929 13.6.09 A UB G2 + 30 C 75 3Cm -1 D 1.2 30 1 4 III, V 
90. Shanthi 22 25680 13.6.09 B UB P - 34 C 75 3Cm -1 - 2.1 34 5 hrs 6   
91. Thenmozhi 21 25691 13.6.09 A B P - 31 C 25 1F -3 H 2.1 34.2 23 8   
92. Muthulakshmi 23 27778 21.07.09 B B P - 34 C 25 1F -2 - 2.2 34.3 3 8   
93. Gomathi 21 31866 28.7.09 B UB P - 34 C 75 3Cm -1 - 2.1 34 6 hrs 6   
94. Revathi 22 34261 7.8.09 A UB P - 32 Br 75 3Cm -1 H 1.6 32.2 2 6   
95. Sumathi 23 34218 6.8.09 B B G2 - 32 C 75 2Cm -2 - 1.6 32 6 hrs 4   
96. Ranganayaki 23 34335 7.8.09 A UB P - 32 C 75 2Cm -1 - 1.4 32.2 2 5   
97. Veeranagammal 22 35048 11.8.09 B B P - 34 C 25 2F -1 - 2.2 34 1 6   
98. Durgadevi 24 35076 12.8.09 A B G2 + 30 C 50 2F -2 H 1.3 30.4 4 4 I 
99. Ilakya 21 35321 13.8.09 B B P - 33 C 75 3Cm -1 - 1.8 23 6 hrs 4   
100. Kavitha 24 35908 18.8.09 A UB P - 32 C 75 3Cm -1 - 1.5 32.2 2 5   
 
 
 
ABBREVIATIONS 
 
DOA   - Date Of Admission     Br -  Breech 
Cx  Eff  -  Cervical Effacement    H -  Headache 
Cx Dil - Cervical Dilatation     D  - Dizziness 
Mat Comp -  Maternal Complication    BP - Hypotension 
B.Wt  -  Birth Weight     S.I -  Skin Irritation 
GA at Del -  Gestational Age at Delivery   T - Tachycardia 
DOP  -  Duration of Prolongation    I - Birth Asphyxia 
Neo   - Neonatal      II - Respiratory Distress Syndrome (RDS) 
UB  - Unbooked      III - Septicemia 
B  - Booked      IV - Intraventricular Hemorrhage 
C  - Cephalic       V - Fetal Death 
